Full Press Release Details
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Par
Par Confirms Validity of OMIDRIA Patents and Agrees
Not to Market a Generic Version of OMIDRIA Until 2032
SEATTLE, WA October 5, 2017 Omeros Corporation (NASDAQ: OMER) today announced that it entered into a settlement agreement with Par
Pharmaceutical, Inc. and its subsidiary Par Sterile Products, LLC (Par), resolving Omeros patent litigation against Par. The litigation concerned Par s filing of an Abbreviated New Drug Application (ANDA) seeking approval from the U.S.
Food and Drug Administration (FDA) to market a generic version of Omeros commercial drug OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3%. In the settlement, Par, which had
previously stipulated to infringement, acknowledges and confirms the validity of all asserted patents for OMIDRIA. The settlement includes a consent judgment filed with the U.S. District Court for the District of Delaware. Unless subsequently
authorized pursuant to terms in the settlement agreement, Par will be prohibited by the judgment from launching a generic version of OMIDRIA until April 1, 2032. The last-to-expire of Omeros Orange Book listed patents for OMIDRIA expires
on October 23, 2033. As part of the settlement agreement, if and when Par eventually enters the market, Par will pay to Omeros a royalty of 15 percent of Par s net sales of any generic version of OMIDRIA until the latest expiration of
Omeros U.S. Patents related to OMIDRIA.
The litigation against Par began in 2015 after Omeros received a Paragraph IV certification from Par in
connection with Par s filing of an ANDA seeking the FDA s approval to market a generic version of OMIDRIA. Over the course of the litigation, Par had conceded that its proposed generic version of OMIDRIA would infringe the Orange
Book-listed patents for OMIDRIA. Par, however, challenged the patents validity. The settlement agreement was entered into after a three-day trial before the U.S. District Court for the District of Delaware in July 2017 and post-trial briefing
but prior to the court issuing a decision. As part of the agreement, Par acknowledges and confirms the validity of each of the patents listed in the Orange Book for OMIDRIA, namely U.S. Patent No. 8,173,707, U.S. Patent No. 8,586,633, U.S.
Patent No. 9,066,856, U.S. Patent No. 9,278,101, U.S. Patent No. 9,399,040, and U.S. Patent No. 9,486,406.
this settlement and what it represents to our company and its shareholders, stated Gregory A. Demopulos M.D., chairman and chief executive officer of Omeros. The settlement affirms our belief in the strength of our patents for OMIDRIA.
Sales of OMIDRIA continue to grow as more and more facilities and surgeons incorporate the product into their cataract surgery routines, improving postoperative outcomes for their patients.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for
large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The company s drug product OMIDRIA
(phenylephrine and ketorolac injection) 1% / 0.3% is marketed for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular
pain. In the European Union, the European Commission has approved OMIDRIA for use in cataract surgery and other IOL replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye
pain. Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington s disease and cognitive impairment; and
addictive and compulsive disorders. The U.S. Food and Drug Administration has granted breakthough therapy, fast-track and orphan drug designations across a number of Omeros clinical programs. In addition, Omeros has a diverse group of
preclinical programs and a proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and corresponding compounds, a number of which are in preclinical development. The company also exclusively
possesses a novel antibody-generating platform.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, which are subject to the safe harbor created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by
terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential,
predict, project, should, will, would and similar expressions and variations thereof. Forward-looking statements are based on management s beliefs and assumptions and on information
available to management only as of the date of this press release. Omeros actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with
product commercialization and commercial operations, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors
described under the heading Risk Factors in the company s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2017. Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations